Suppr超能文献

强效且选择性的IRAK4酰胺吡唑抑制剂,在啮齿动物炎症模型中具有疗效。

Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.

作者信息

McElroy William T, Tan Zheng, Ho Ginny, Paliwal Sunil, Li Guoqing, Seganish W Michael, Tulshian Deen, Tata James, Fischmann Thierry O, Sondey Christopher, Bian Hong, Bober Loretta, Jackson James, Garlisi Charles G, Devito Kristine, Fossetta James, Lundell Daniel, Niu Xiaoda

机构信息

Discovery Chemistry, Structural Chemistry, In Vitro Pharmacology, and Respiratory and Immunology, Merck Research Laboratories , 2015 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.

出版信息

ACS Med Chem Lett. 2015 May 12;6(6):677-82. doi: 10.1021/acsmedchemlett.5b00106. eCollection 2015 Jun 11.

Abstract

IRAK4 is a critical upstream kinase in the IL-1R/TLR signaling pathway. Inhibition of IRAK4 is hypothesized to be beneficial in the treatment of autoimmune related disorders. A screening campaign identified a pyrazole class of IRAK4 inhibitors that were determined by X-ray crystallography to exhibit an unusual binding mode. SAR efforts focused on the identification of a potent and selective inhibitor with good aqueous solubility and rodent pharmacokinetics. Pyrazole C-3 piperidines were well tolerated, with N-sulfonyl analogues generally having good rodent oral exposure but poor solubility. N-Alkyl piperidines exhibited excellent solubility and reduced exposure. Pyrazoles possessing N-1 pyridine and fluorophenyl substituents were among the most active. Piperazine 32 was a potent enzyme inhibitor with good cellular activity. Compound 32 reduced the in vivo production of proinflammatory cytokines and was orally efficacious in a mouse antibody induced arthritis disease model of inflammation.

摘要

IRAK4是白细胞介素-1受体/ Toll样受体(IL-1R/TLR)信号通路中的关键上游激酶。据推测,抑制IRAK4对自身免疫相关疾病的治疗有益。一项筛选活动鉴定出一类吡唑类IRAK4抑制剂,通过X射线晶体学确定其具有不同寻常的结合模式。构效关系研究致力于鉴定出一种具有良好水溶性和啮齿动物药代动力学的强效且选择性的抑制剂。吡唑C-3哌啶耐受性良好,N-磺酰基类似物通常具有良好的啮齿动物口服暴露量,但溶解度较差。N-烷基哌啶表现出优异的溶解度,但暴露量降低。具有N-1吡啶和氟苯基取代基的吡唑是活性最高的化合物之一。哌嗪32是一种具有良好细胞活性的强效酶抑制剂。化合物32可降低体内促炎细胞因子的产生,并且在小鼠抗体诱导的关节炎炎症疾病模型中口服有效。

相似文献

1
Potent and Selective Amidopyrazole Inhibitors of IRAK4 That Are Efficacious in a Rodent Model of Inflammation.
ACS Med Chem Lett. 2015 May 12;6(6):677-82. doi: 10.1021/acsmedchemlett.5b00106. eCollection 2015 Jun 11.
2
Bicyclic pyrimidine compounds as potent IRAK4 inhibitors.
Bioorg Med Chem Lett. 2022 Oct 1;73:128900. doi: 10.1016/j.bmcl.2022.128900. Epub 2022 Jul 18.
3
Synthesis and evaluation of dihydrofuro[2,3-b]pyridine derivatives as potent IRAK4 inhibitors.
Eur J Med Chem. 2023 Oct 5;258:115616. doi: 10.1016/j.ejmech.2023.115616. Epub 2023 Jun 30.
4
Discovery of 5-Amino-N-(1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidine-3-carboxamide Inhibitors of IRAK4.
ACS Med Chem Lett. 2015 Apr 20;6(6):683-8. doi: 10.1021/acsmedchemlett.5b00107. eCollection 2015 Jun 11.
5
Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors.
Bioorg Med Chem Lett. 2016 Sep 1;26(17):4250-5. doi: 10.1016/j.bmcl.2016.07.048. Epub 2016 Jul 22.
6
Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.
Bioorg Med Chem Lett. 2017 Nov 1;27(21):4908-4913. doi: 10.1016/j.bmcl.2017.09.029. Epub 2017 Sep 18.
7
Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
Expert Opin Ther Pat. 2019 Apr;29(4):243-259. doi: 10.1080/13543776.2019.1597850. Epub 2019 Mar 29.
8
Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Bioorg Med Chem Lett. 2014 May 1;24(9):2066-72. doi: 10.1016/j.bmcl.2014.03.056. Epub 2014 Mar 29.
9
Identification of quinazoline based inhibitors of IRAK4 for the treatment of inflammation.
Bioorg Med Chem Lett. 2017 Jun 15;27(12):2721-2726. doi: 10.1016/j.bmcl.2017.04.050. Epub 2017 Apr 18.

引用本文的文献

1
Discovery of 5-Aryl-2,4-diaminopyrimidine Compounds as Potent and Selective IRAK4 Inhibitors.
ACS Med Chem Lett. 2022 Apr 4;13(4):714-719. doi: 10.1021/acsmedchemlett.2c00056. eCollection 2022 Apr 14.
3
Substituted Pyrazoles and Their Heteroannulated Analogs-Recent Syntheses and Biological Activities.
Molecules. 2021 Aug 18;26(16):4995. doi: 10.3390/molecules26164995.
4
Rapid Evaluation of Small Molecule Cellular Target Engagement with a Luminescent Thermal Shift Assay.
ACS Med Chem Lett. 2021 Jul 12;12(8):1288-1294. doi: 10.1021/acsmedchemlett.1c00276. eCollection 2021 Aug 12.
6
Dimethyl Fumarate Disrupts Human Innate Immune Signaling by Targeting the IRAK4-MyD88 Complex.
J Immunol. 2019 May 1;202(9):2737-2746. doi: 10.4049/jimmunol.1801627. Epub 2019 Mar 18.
7
Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4).
J Biol Chem. 2019 Mar 22;294(12):4511-4519. doi: 10.1074/jbc.RA118.005428. Epub 2019 Jan 24.
9
Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategy.
Oncotarget. 2018 Sep 7;9(70):33416-33439. doi: 10.18632/oncotarget.26058.

本文引用的文献

2
Inflammation, ageing and chronic disease.
Curr Opin Immunol. 2014 Aug;29:23-8. doi: 10.1016/j.coi.2014.03.007. Epub 2014 Apr 22.
3
Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4.
Bioorg Med Chem Lett. 2014 May 1;24(9):2066-72. doi: 10.1016/j.bmcl.2014.03.056. Epub 2014 Mar 29.
4
A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.
Am J Respir Cell Mol Biol. 2014 Aug;51(2):191-200. doi: 10.1165/rcmb.2013-0411OC.
5
Jakpot! New small molecules in autoimmune and inflammatory diseases.
Exp Dermatol. 2014 Jan;23(1):7-11. doi: 10.1111/exd.12265.
6
Targeting Toll-like receptors with small molecule agents.
Chem Soc Rev. 2013 Jun 21;42(12):4859-66. doi: 10.1039/c3cs60039d.
7
The problem of choice: current biologic agents and future prospects in RA.
Nat Rev Rheumatol. 2013 Mar;9(3):154-63. doi: 10.1038/nrrheum.2013.8. Epub 2013 Feb 19.
8
Cancer and inflammation: an old intuition with rapidly evolving new concepts.
Annu Rev Immunol. 2012;30:677-706. doi: 10.1146/annurev-immunol-020711-075008. Epub 2012 Jan 6.
9
The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design?
Drug Discov Today. 2009 Nov;14(21-22):1011-20. doi: 10.1016/j.drudis.2009.07.014. Epub 2009 Sep 1.
10
Animal models of rheumatoid arthritis.
Eur J Immunol. 2009 Aug;39(8):2040-4. doi: 10.1002/eji.200939578.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验